ArticleInternational journal of clinical oncology2026
Therapy-related myeloid neoplasms following treatment for high-risk gestational trophoblastic neoplasia: a case series and retrospective analysis.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapy-related myeloid neoplasms (t-MNs), including therapy-related myelodysplastic syndrome and therapy-related acute myeloid leukemia, are rare but severe late complications of cytotoxic chemotherapy. This study aimed to identify the occurrence of t-MNs in patients with high-risk gestational trophoblastic neoplasia (GTN) treated at our institution.
methodsA retrospective review was conducted in 47 patients with high-risk GTN treated between 1990 and 2023. Clinical data included age, antecedent pregnancy, International Federation of Gynecology and Obstetrics stage, World Health Organization prognostic score, chemotherapy regimen, cumulative etoposide dose, and outcomes. Patients who developed t-MN were compared with those who did not.
resultsAmong the 47 patients, 34 (72%) achieved cure without relapse, 6 (13%) achieved cure following relapse, and 7 (15%) did not achieve cure. Four patients (8.5%) developed t-MN after prolonged chemotherapy. The latency from initiation of GTN treatment to t-MN onset ranged from 3 to 5 years, whereas the interval from the last chemotherapy administration to diagnosis ranged from immediately after treatment completion to 20 months. All four patients received multi-agent, etoposide-containing regimens with cumulative doses ≥ 6,000 mg/m
conclusionAlthough combination chemotherapy remains essential for high-risk GTN, exposure to high cumulative doses of etoposide confers a risk of secondary t-MNs. Long-term hematologic surveillance and less leukemogenic strategies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.